Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Añadir filtros








Intervalo de año
1.
Yeungnam University Journal of Medicine ; : 138-142, 2015.
Artículo en Inglés | WPRIM | ID: wpr-213780

RESUMEN

L-thyroxine (LT4) withdrawal prior to radioactive iodine (RAI) ablation therapy is a commonly used method for successful treatment of patients with papillary thyroid cancer (PTC). However, a prolonged period of hypothyroidism induced by LT4 withdrawal is sometimes associated with impaired quality of life and cardiopulmonary dysfunction in PTC patients. Furthermore, LT4 withdrawal may have a trophic effect on residual cancer by means of increased thyrotropin. We report on 2 cases of metastatic PTC patients with malignant pleural effusion (MPE) whose disease showed rapid worsening after LT4 withdrawal and RAI therapy. The first case is a 65-year-old woman who had PTC with multiple distant metastases and MPE. During LT4 withdrawal for RAI therapy, MPE showed rapid worsening, and the patient required repetitive therapeutic thoracentesis. The second case is a 49-year-old woman with PTC who underwent 3 additional operations for cancer recurrence in the neck lymph nodes and 6 times of RAI treatments. While preparing for the 7th RAI treatment by withdrawing LT4, she developed MPE which became progressively aggravated after RAI therapy. Both patients experienced increased pleural effusion during the LT4 withdrawal period and a rise in the thyroglobulin level was observed after RAI therapy. MPE was not controlled with therapeutic thoracentesis and pleurodesis. Eventually, both patients died of rapid disease progression after RAI therapy. In summary, LT4 withdrawal may have an adverse effect on metastatic PTC patients, particularly those with MPE.


Asunto(s)
Anciano , Femenino , Humanos , Persona de Mediana Edad , Progresión de la Enfermedad , Hipotiroidismo , Yodo , Ganglios Linfáticos , Cuello , Metástasis de la Neoplasia , Neoplasia Residual , Derrame Pleural , Derrame Pleural Maligno , Pleurodesia , Calidad de Vida , Recurrencia , Tiroglobulina , Glándula Tiroides , Hormonas Tiroideas , Neoplasias de la Tiroides , Tirotropina , Tiroxina
2.
Korean Journal of Medicine ; : 447-452, 2015.
Artículo en Coreano | WPRIM | ID: wpr-180820

RESUMEN

Cryptococcus neoformans is a fungus that causes opportunistic infections in immunocompromised hosts. Skin lesions are found in 10-20% of systemic cryptococcal infections, usually secondary to cryptococcemia, while primary cutaneous cryptococcosis with cryptococcemia is very rare. We report a case of rapidly spreading cryptococcal cellulitis in a 64-year-old male on maintenance hemodialysis taking steroids for encapsulated peritoneal sclerosis. Bluish bullous cellulitis developed on the left forearm and spread rapidly to the other forearm. We identified C. neoformans in the blood and skin lesions. We treated him successfully with liposomal amphotericin B and fluconazole for 15 months. We also review the literature.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Anfotericina B , Celulitis (Flemón) , Criptococosis , Cryptococcus neoformans , Fluconazol , Antebrazo , Hongos , Huésped Inmunocomprometido , Infecciones Oportunistas , Fibrosis Peritoneal , Diálisis Renal , Piel , Esteroides
3.
Chonnam Medical Journal ; : 115-118, 2014.
Artículo en Inglés | WPRIM | ID: wpr-788292

RESUMEN

The use of anti-tumor necrosis factor (anti-TNF) agents for rheumatoid arthritis (RA) patients who are refractory to disease-modifying anti-rheumatic drugs is gradually increasing. Etanercept is the first anti-TNF agent to be approved for RA treatment and is also the most widely used. However, aggravation of interstitial lung disease after etanercept treatment in RA patients has been reported recently. We report the first case of recurrent spontaneous pneumothorax with progression of interstitial lung disease after initiating etanercept therapy. The withdrawal of etanercept and a change to adalimumab, a different class of TNF inhibitor, achieved clinical stabilization.


Asunto(s)
Humanos , Antirreumáticos , Artritis Reumatoide , Enfermedades Pulmonares Intersticiales , Necrosis , Neumotórax , Adalimumab , Etanercept
4.
Chonnam Medical Journal ; : 115-118, 2014.
Artículo en Inglés | WPRIM | ID: wpr-75445

RESUMEN

The use of anti-tumor necrosis factor (anti-TNF) agents for rheumatoid arthritis (RA) patients who are refractory to disease-modifying anti-rheumatic drugs is gradually increasing. Etanercept is the first anti-TNF agent to be approved for RA treatment and is also the most widely used. However, aggravation of interstitial lung disease after etanercept treatment in RA patients has been reported recently. We report the first case of recurrent spontaneous pneumothorax with progression of interstitial lung disease after initiating etanercept therapy. The withdrawal of etanercept and a change to adalimumab, a different class of TNF inhibitor, achieved clinical stabilization.


Asunto(s)
Humanos , Antirreumáticos , Artritis Reumatoide , Enfermedades Pulmonares Intersticiales , Necrosis , Neumotórax , Adalimumab , Etanercept
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA